⌕
AnaptysBio · ANAB · Nasdaq
Tenet 53 · Mixed
Compare
$45.61−0.26%At closeTenet 53 · Mixed
$45.61−0.12 (−0.26%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

AnaptysBio (ANAB) Stock

AnaptysBio (ANAB) closed at $45.61 on Nov 17, 2026; its Tenet Score is 53 of 100 against 340 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

17 figures withheld by our checks. Each blank figure names its reason.

Key stats

Close
$45.61
Nov 17, 2026
Market cap
$1.4B
share price × the latest quarter's diluted weighted-average share count (vendor)
52-week range
32.96 – 73.30
low → high · as of close, Nov 16, 2026
Tenet Score
53/100
Mixed · 340 Healthcare peers

Industry: Drugs

AnaptysBio Inc scores 53/100. Mixed. Strongest on financial health, value is the soft spot versus 340 Healthcare peers.

Tenet Score · vs sector

n=340
53/ 100
Mixed
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
29
Quality
49
Health
70
Growth
65

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
ValueFQualityDHealthBGrowthCMomentumB
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/E
—
Not meaningful: the company made a loss.
P/B
36.5×
fiscal year to Dec 31, 2025 · as of close, Nov 16, 2026
P/S
5.8×
price to sales, fiscal 2025 · as of close, Nov 16, 2026
ROE
−24%
fiscal year to Dec 31, 2025
Operating margin
20.4%
before interest and tax
Net margin
−5.6%
fiscal year to Dec 31, 2025
Current ratio
9.07
fiscal year to Dec 31, 2025
Net debt / EBITDA
−6.2×
fiscal year to Dec 31, 2025
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.
Div yield
—
no yield on file

The whole report, at a glance · every card is a live peek, click any to open the section

About AnaptysBio Inc

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R)…

Composite computed Nov 16, 2026 · peer basis: Healthcare (n=340) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 76 US ETFs · top wrappers by weightSee all ETFs holding ANAB →

Similar-sized companies in Drugs

The 10 companies in this industry closest in market cap, as of Nov 16, 2026.

What sector and industry is AnaptysBio in?

AnaptysBio is in the Healthcare sector and the Drugs industry.

What is AnaptysBio's Tenet Score?

AnaptysBio's Tenet Score is 53 out of 100, ranked against 340 Healthcare peers as of Nov 16, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.